MRVI Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
45.9M
-10.9%
51.4M
-21.9%
65.8M
+32.0%
49.9M
+19.8%
41.6M
Cost of Revenue
29.7M
-3.7%
30.8M
-4.2%
32.1M
-13.2%
37.0M
+2.9%
36.0M
Gross Profit
16.2M
-21.6%
20.6M
-38.7%
33.7M
+162.4%
12.8M
+127.1%
5.7M
Operating Expenses
36.8M
+3.0%
35.7M
-0.3%
35.9M
-49.9%
71.6M
+53.4%
46.7M
R&D
3.4M
-8.4%
3.7M
-4.8%
3.9M
+2.7%
3.8M
-1.5%
3.8M
SG&A
30.5M
-4.9%
32.1M
+10.2%
29.1M
-7.9%
31.6M
-10.9%
35.5M
Operating Income
-20619000
-36.6%
-15089000
-599.2%
-2158000
+96.3%
-58795000
-43.3%
-41031000
EBITDA
-5497000
-64.6%
-3340000
-127.6%
12.1M
+219.9%
-10084000
+50.7%
-20461000
Net Income
-24000000
-11.0%
-21631000
-239.2%
-6377000
+89.9%
-63015000
-39.9%
-45057000
EPS (Basic)
$-0.09
-12.5%
$-0.08
-300.0%
$-0.02
+92.0%
$-0.25
-38.9%
$-0.18
EPS (Diluted)
$-0.09
-12.5%
$-0.08
-300.0%
$-0.02
+92.0%
$-0.25
-38.9%
$-0.18
Shares (Diluted)
149.1M
+0.7%
148.0M
+1.1%
146.4M
+0.9%
145.1M
+0.3%
144.7M
Maravai LifeSciences (MRVI) — Financials